TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Metabolic adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak knee angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bochum Matrices Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neointimal healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time until clinical worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with treatment-emergent (serious) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants With A1C < 8%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Actual FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: % change from Baseline in Actual FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in FEV1 % predicted normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participants Experiencing a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limiting Toxicity Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation between expected and real position of cranial nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient-perceived Mobility (PLUS-M)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-perceived Activity Restrictions (Revised TAPES-AR Subscale)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Amount of Tissue Obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Receiving Diagnosis From Muscle Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle oxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin scale scores (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with symptomatic intracerebral hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Death related to the index stroke within 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Neutrophil recovery of ≥500/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neutrophil phenotype and redistribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of treatment discontinuation due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: IUD expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Overall Toric Lens Fit Acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Vision While Driving During the Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood-oxygen-level dependent signal in the amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of NM21-1480
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Best Overall Response of NM21-1480
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Response Rate of NM21-1480
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Motor imagery ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 years overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Device related Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Curve progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo-corrected change in Fridericia-corrected QTc (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalisation due to congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of Pathological Complete Response Negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with Complete Hematologic Remission (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Classification of Complete Cytogenetic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic accuracy (true/false positive/negative rates)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of M-Inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of major cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of efficacy of treatment (incidence of major events)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report of physical activity behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum tolerated dose of nivolumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to liver transplant or death
Endpoint domain: Mortality/survival
Primary endpoint: Patient's health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of suppression of viral load to less than 80 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average change of CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Two-year incidence rate of immunodeficiency related clinical conditions
Endpoint domain: Mortality/survival
Primary endpoint: Uptake of Genetic Counseling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Coverage of the prostate by the prescribed radiation dose at V100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: summary of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: clinically significant blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinically significant pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinically significant 12-lead electrocardiograms (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinically significant hematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clinically significant clinical chemistry laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy and safety of Nexagon® for PED treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-OP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine production of isolated monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Protein Concentration in Broncho-alveolar Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Testing Positive for Mtb at Day 84
Endpoint domain: Adverse events/effects
Primary endpoint: Meibomian Glands Yielding Liquid Secretion (MGYLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of detrusor underactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic presentation of Detrusor underactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urodynamics parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collection of blood and tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Birth <=32 6/7 Weeks Gestation
Endpoint domain: Mortality/survival
Primary endpoint: restenosis/occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Body mass index percentile ranking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of Avelumab
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of inappropriate prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number, frequency and type of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Rotavirus Gastroenteritis Associated Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Regional Blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Major Arrhythmic Events (MAEs)
Endpoint domain: Mortality/survival
Primary endpoint: Apnea hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of catheters presenting complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in motivation to quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in readiness to change behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in interprofessional collaboration
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Presence of at least one fracture in the dorsal spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of at least one fracture in the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of at least one fracture of the pelvis and proximal femurs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of at least one fracture of the hands/wrists
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of at least one fracture of the feet/ankles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: unstable vital signs, hypoxemia or hypercapnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quantitative motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in upper limb motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6 minute walk test in ambulatory patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of VTE diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ability of NIR imaging to show tumoral volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of sirolimus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pharmacokinetics of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics of omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity of the Better-seeing Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ocular discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUC(0-tlqc) for Vortioxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Vortioxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in % of Treg Cells in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Basic Mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Choroidal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major malformations
Endpoint domain: Adverse events/effects
Primary endpoint: Primary cecal pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Young Mania Rating Scale (YMRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum serum concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast (area under the curve from the time of dosing to the last measurable concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax (time to reach maximum plasma concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL/F (Clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder catheterization success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall pupil dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and frequency of Pain pills taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: amount of transfused red blood cell concentrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Protein expression levels of TRPM7 and MLKL in colorectal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratios of Ki67:BAX and Ki67:TUNEL in rectal epithelial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of Cox2 in rectal epithelia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional content of foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Macular pigment ocular density (MPOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multidimensional Measure of Informed Choice (MMIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stone free rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Result of Go-Nogo test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in FACIT-fatigue Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Effectiveness of TheraSphere® treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Plasma Concentration [Cmax] of tofacitinib from single oral dosing in Period 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve [AUC] of tofacitinib from single oral dosing in Period 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of Tofacitinib Citrate Topical Gel 3.2% as assessed by treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: mutants streptococcus count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: fMRI brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: solitary elective volume recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological anti-tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in pressure pain threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluid removed along with hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of mean arterial pressure along with hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes of heart rate along with hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes of stroke volume along with hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes of cardiac output along with hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of adenocarcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Number of Squamous Cell Carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: The slit lamp examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The intraocular pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: biochemical analysis of wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fistula healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Study Participants Who Tolerated a Single Daily Oral ST-246 Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of meditating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change of running time scores at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of the plasma lactic acid clearance rate after running at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of red blood cells after running at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PTSD symptom severity (PCL-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychotic Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dissociation (Shut-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in α-synuclein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Tau concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Venous graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Correct Identification of Photographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous treatment satisfaction questionnaire-early
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of target vein treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to PACU Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate fixation to the underlying bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health status and functional outcome of patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: wear rate of the Vitamin E polyethylene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression through the HBV care cascade post-diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of bipolar disorder or related mental illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of surgical delay (Bladder cohort)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of surgical complications (Bladder cohort)
Endpoint domain: Adverse events/effects
Primary endpoint: Neuroimaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood oxygenation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Readmission at 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the bacterial biofilm depth adherent to the colonic epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: quantitative change in bacterial biomass adherent to the colonic epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes